Aclaris Therapeutics (ACRS) Total Liabilities (2014 - 2026)

Aclaris Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $55.1 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 1.93% year-over-year to $55.1 million; the TTM figure through Mar 2026 stood at $55.1 million (up 1.93% YoY), while the FY2025 annual figure was $57.4 million, down 11.42% from the prior year.
• Total Liabilities was $55.1 million for Q1 2026 at Aclaris Therapeutics, down from $57.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $64.8 million in Q4 2024 to a low of $27.2 million in Q2 2024.
• Historically, Total Liabilities has averaged $50.6 million across 5 years, with a median of $54.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities plunged 51.25% in 2024, then surged 110.68% in 2025.
• A 5-year view of Total Liabilities shows it stood at $57.0 million in 2022, then decreased by 29.4% to $40.2 million in 2023, then jumped by 61.02% to $64.8 million in 2024, then retreated by 11.42% to $57.4 million in 2025, then fell by 4.02% to $55.1 million in 2026.
• The last three Total Liabilities figures came in at $55.1 million (Q1 2026), $57.4 million (Q4 2025), and $55.4 million (Q3 2025), per Business Quant data.